Product Description
Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist. Capsaicin is a chili pepper extract with analgesic properties. Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin)
Mechanisms of Action: TRPV1 Agonist,GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: NeurogesX
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Neuralgia|Neuropathic Pain|Peripheral Nervous System Diseases
Phase 2: Animal Hypersensitivity|Asthma|Chronic Cough|Chronic Pain|Environmental Hypersensitivity|Evans Syndrome|Fish Hypersensitivity|Food Hypersensitivity|Labor Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CAPNEUCHIM | P3 |
Not yet recruiting |
Chemotherapy-induced Peripheral Neuropathy|Peripheral Nervous System Diseases |
2027-03-01 |
|
| AV001 | P3 |
Recruiting |
Neuropathic Pain|Neuralgia |
2024-10-01 |
95% |
| NCT04125563 | P2 |
Active, not recruiting |
Chronic Pain|Environmental Hypersensitivity|Asthma|Evans Syndrome|Animal Hypersensitivity|Chronic Cough|Labor Pain|Food Hypersensitivity|Fish Hypersensitivity|Neuropathic Pain |
2024-06-30 |
|
| 2021-001409-64 | P3 |
Active, not recruiting |
Neuropathic Pain |
2024-01-10 |